Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
Analysis
All Analysis
Basic Materials
Biotech
Bonds
Closed End Funds
Commodities
Communication Services
Consumer
Consumer Staples
Cryptocurrency
Dividend Ideas
Dividend Quick Picks
Dividend Strategy
Dividends
Economy
Editors' Picks
Energy
ETF Analysis
ETFs and Funds
Financial Advisor
Financials
Fixed Income
Forex
Gold & Precious Metals
Growth
Healthcare
Industrial
Investing Strategy
IPOs
Long Ideas
Market Outlook
Micro-Caps
Mutual Funds
Portfolio Strategy
Quick Picks & Lists
Real Estate
REITs
Retirement
Small-Caps
Stock Ideas
Tech
Utilities
Value
Micro-Cap Stocks
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
CuriosityStream: The Surprise 10% Dividend Is Why Micro-Caps Can Be So Lucrative
Pulsar Helium: The Base Idea Worries Me
Nkarta: NK Cell Therapy Advancement On Two Fronts
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Fisker: Precarious Situation
Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
bluebird bio Is Priced Below IP Value
OptimizeRx: Exponential Growth Drives The Valuation Cheaper
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders
Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
CuriosityStream: Too Cheap To Ignore
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Ocean Biomedical: Shooting Upward, But Not Somewhere I Want To Be (Rating Upgrade)
Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
Arq, Inc.: A Pot Of Gold At The End Of The Rainbow
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments
Logan Energy: Experienced Management Is The Big Advantage
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Cumulus Media: A Riddle, Wrapped In A Mystery, Inside An Enigma
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Canoo: Avoid After Reverse Stock Split
LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program
Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid
Boundless Bio Starts $100 Million U.S. IPO Plan
Cherry Hill Mortgage Investment: One Preferred Is Better Than The Other
Yangarra Resources: Pause In Growth Strategy
Village Farms Has An Extremely Low Valuation
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price
enVVeno: The Road To Approval Seems Open From Here On
1
2
Next
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.